Merck & Co., Inc. (NYSE:MRK) Given Daily Media Impact Rating of 0.21

News stories about Merck & Co., Inc. (NYSE:MRK) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Merck & Co., Inc. earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.6252976308133 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of Merck & Co., Inc. (MRK) opened at $58.66 on Friday. Merck & Co., Inc. has a 12 month low of $53.63 and a 12 month high of $66.80. The stock has a market capitalization of $159,990.00, a PE ratio of 56.95, a price-to-earnings-growth ratio of 2.87 and a beta of 0.76. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.57.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.08. Merck & Co., Inc. had a return on equity of 27.08% and a net margin of 11.60%. The firm had revenue of $10.33 billion for the quarter, compared to the consensus estimate of $10.54 billion. During the same quarter last year, the business posted $1.07 EPS. The company’s revenue for the quarter was down 2.0% on a year-over-year basis. equities research analysts forecast that Merck & Co., Inc. will post 3.95 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Monday, January 8th. Shareholders of record on Friday, December 15th were paid a $0.48 dividend. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.47. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $1.92 annualized dividend and a dividend yield of 3.27%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 186.41%.

Merck & Co., Inc. declared that its Board of Directors has authorized a stock buyback plan on Tuesday, November 28th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

MRK has been the topic of several research analyst reports. Cowen reaffirmed a “hold” rating and set a $70.00 price objective on shares of Merck & Co., Inc. in a research note on Friday, November 3rd. BMO Capital Markets set a $68.00 price objective on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Wednesday, December 13th. JPMorgan Chase & Co. set a $70.00 price objective on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Sunday, October 29th. Jefferies Group reaffirmed a “sell” rating and set a $55.00 price objective on shares of Merck & Co., Inc. in a research note on Friday, October 20th. Finally, Bank of America initiated coverage on Merck & Co., Inc. in a research note on Tuesday, November 28th. They set a “buy” rating and a $64.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $66.06.

In other news, Director Thomas H. Glocer sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.25% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-merck-co-inc-mrk-stock-price.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Insider Buying and Selling by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply